| Company/Division name | Mölnlycke Health Care |
| Parent company | Mölnlycke Health Care |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Capital investment ($): | 135 |
| Country(ies) from which reshored: | Sweden |
| City reshored to: | Brunswick |
| State(s) reshored to: | ME |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | medical supplies |
| What non-domestic negative factors made offshoring less attractive? | Green considerations, Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Lead time/Time to market, Proximity to customers/market |
